文献速递肿瘤 PET/CT核素与放射性配体治疗

FAP靶向诊疗前临床模型的体外与离体评估:差异及其对放射性示踪剂评价的意义

In vitro and ex vivo evaluation of preclinical models for FAP-targeted theranostics: differences and relevance for radiotracer evaluation.
PubMed 文献 · EJNMMI Res · 2024-12-24

该研究比较了FAP转导的HT1080-huFAP与HEK293-huFAP细胞、内源性表达FAP的U-87 MG癌细胞与PS-1胰腺星状细胞中FAP示踪剂的行为,使用[111In]In-FAPI-46和荧光FAP靶向示踪剂RTX-1370S进行体外与离体结合/摄取及定位比较,并以RT-qPCR和抗FAP免疫组化测定FAP表达。结果显示FAP表达最高不等于示踪剂摄取最高,不同模型间FAP与示踪剂相互作用存在差异,提示需适当选择模型且跨研究比较困难。

要点

  • FAP表达最高见于HEK293-huFAP细胞及其异种移植瘤,但[111In]In-FAPI-46摄取最高见于HT1080-huFAP。
  • U-87 MG与PS-1细胞摄取较HT1080-huFAP低6-10倍,但离体U-87 MG异种移植瘤结合仅低2倍。
  • 不同模型中FAP与FAP靶向示踪剂相互作用存在差异,跨研究比较困难。

核心结论

  • FAP与FAP靶向示踪剂的相互作用在不同模型间存在差异,表明需适当选择模型,且使用不同模型的研究结果间比较困难。

研究设计与样本

  • 研究比较了FAP转导的HT1080-huFAP与HEK293-huFAP细胞以及内源性表达FAP的U-87 MG癌细胞与PS-1胰腺星状细胞。
  • 使用[111In]In-FAPI-46和荧光FAP靶向示踪剂RTX-1370S进行体外与离体示踪剂结合/摄取及定位比较。
  • 以RT-qPCR和抗FAP免疫组化测定FAP表达。

主要发现

  • FAP表达在HEK293-huFAP细胞及其细胞系来源异种移植瘤中最高,但并未导致最高示踪剂摄取。
  • [111In]In-FAPI-46摄取在HT1080-huFAP中最高,HEK293-huFAP紧随其后,U-87 MG与PS-1细胞摄取低6-10倍。
  • 离体U-87 MG异种移植瘤结合较HT1080-huFAP与HEK293-huFAP异种移植瘤仅低2倍,主要因该细胞系吸引小鼠成纤维细胞,RT-qPCR与免疫组化研究证实了这一点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibroblast activation protein (FAP) is an attractive target for cancer theranostics. Although FAP-targeted nuclear imaging demonstrated promising clinical results, only sub-optimal results are reported for targeted radionuclide therapy (TRT). Preclinical research is crucial in selecting promising FAP-targeted radiopharmaceuticals and for obtaining an increased understanding of factors essential for FAP-TRT improvement. FAP is mainly expressed by cancer-associated fibroblasts in the tumor stroma and less on cancer cells themselves. Therefore, other (complex) factors impact FAP-TRT efficacy compared to currently clinically applied TRT strategies. For accurate evaluation of these aspects, selection of a representative preclinical model is important. Currently mainly human cancer cell lines transduced to (over)express FAP are applied, lacking clinical representation. It is unclear how these and more physiological FAP-expressing models compare to each other, and whether/how the model influences the study outcome. We aimed to address this by comparing FAP tracer behavior in FAP-transduced HT1080-huFAP and HEK293-huFAP cells, and endogenous FAP-expressing U-87 MG cancer cells and PS-1 pancreatic stellate cells. [111In]In-FAPI-46 and a fluorescent FAP-targeted tracer (RTX-1370S) were used to compare tracer binding/uptake and localization in vitro and ex vivo. Additionally, FAP expression was determined with RT-qPCR and anti-FAP IHC. RESULTS: Although FAP expression was highest in HEK293-huFAP cells and cell line derived xenografts, this did not result in the highest tracer uptake. [111In]In-FAPI-46 uptake was highest in HT1080-huFAP, closely followed by HEK293-huFAP, and a 6-10-fold lower uptake for U-87 MG and PS-1 cells. However, ex vivo U-87 MG xenografts only showed a 2-fold lower binding compared to HT1080-huFAP and HEK293-huFAP xenografts, mainly because the cell line attracts murine fibroblasts as demonstrated in our RT-qPCR and IHC studies. CONCLUSIONS: The interaction between FAP and FAP-targeted tracers differs between models, indicating the need for appropriate model selection and that comparing results across studies using different models is difficult.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. van der Heide CD, Campeiro JD, Ruigrok EAM, et al. In vitro and ex vivo evaluation of preclinical models for FAP-targeted theranostics: differences and relevance for radiotracer evaluation. EJNMMI Res. 2024. PMID: 39718718. doi:10.1186/s13550-024-01191-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。